Marksans Pharma Limited is an India-based holding company. The Company is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations. The Company manufactures products for segments, such as pain management, cough and cold, diabetes, cardiovascular, central nervous system, antibiotics, gastrointestinal, anti-allergic and oncology.
The Company is engaged in research and development, and offers contract research and manufacturing services to global pharmaceutical companies. The Company has a manufacturing facility for oral solids and soft gelatin capsules in Goa, India, a manufacturing facility for liquids/ointments/sachets at Southport, the United Kingdom, and a solid oral dosage manufacturing facility in New York, the United States. It supplies products to more than 25 countries. Its subsidiaries include Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (UK) Limited.
The Company is engaged in research and development, and offers contract research and manufacturing services to global pharmaceutical companies. The Company has a manufacturing facility for oral solids and soft gelatin capsules in Goa, India, a manufacturing facility for liquids/ointments/sachets at Southport, the United Kingdom, and a solid oral dosage manufacturing facility in New York, the United States. It supplies products to more than 25 countries. Its subsidiaries include Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (UK) Limited.
